Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Substantiation for Dietary Supplement Claims Made Under the Federal Food, Drug, and Cosmetic Act, 7610-7612 [2015-02787]
Download as PDF
7610
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Recall
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total hours
Firm Initiated Recall (21 CFR 7.46) and Recall Communications (21 CFR 7.49) ...................................................
Recall Status Reports (21 CFR 7.53) ..................................
Termination of a Recall (21 CFR 7.55(b)) ...........................
3,801
3,801
3,801
1
13
1
3,801
49,413
3,801
25
10
10
95,025
494,130
38,010
Total ..............................................................................
........................
........................
........................
........................
627,165
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
total number of annual responses equal
95,025. The average burden hour person
response was 30 and has decreased by
5.
I. Total Annual Reporting
A. Firm Initiated Recall and Recall
Communications
Request firms voluntarily remove or
correct foods and drugs (human or
animal), cosmetics, medical devices,
biologics, and tobacco to immediately
notify the appropriate FDA District
Office of such actions. The firm is to
provide complete details of the recall
reason, risk evaluation, quantity
produced, distribution information,
firms’ recall strategy and a contact
official as well as requires firms to
notify their direct accounts of the recall
and to provide recipients with a ready
means of reporting to the recalling firm.
Under these portions of the collection of
information, the Agency estimates it
will receive 3,801 responses annually
based on the average number of recalls
over the last 3 fiscal years. The number
of responses multiplied by the number
of respondents equal 3,801. The average
burden hours of 25 multiplied by the
B. Recall Status Reports
Request that recalling firms provide
periodic status reports so FDA can
ascertain the progress of the recall. This
request only applies to firms with active
recalls, and is estimated to be reported
every 2 to 4 weeks. This collection of
information will generate approximately
3,801 responses annually, based on the
average number of recalls over the last
3 fiscal years (11,403). The number of
respondents multiplied by the number
of responses per respondents (13) equal
a total number of annual responses of
49,413. The total number of responses
49,413 with an average burden hours of
10 per response equal a total of 494,130
total hours.
C. Termination of a Recall
Provide the firms an opportunity to
request in writing that FDA end the
recall. The Agency estimates it will
receive 3,801 responses annually based
on the average number of terminations
over the past 3 fiscal years. The total
annual responses of 3,801 multiplied by
the average burden hours of 10 per
response equal a total number of hours
of 38,010.
II. Total Annual Third-Party Disclosure
Burden
Recall Communications. Request
firms to notify their consignees of the
recall and to provide recipients with a
ready means of reporting to the recalling
firm. Under this portion of the
collection of information, the Agency
estimates firms will provide 1,691,445
notifications annually based on the
number of respondents/consignees
(3,807) multiplied by the number of
disclosures per respondent (445). The
total number of hours is 94,721 (based
on 1,691,445 multiplied by 0.056
hours).
TABLE 2—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN
Number of
respondents
Number of
disclosures
per
respondent
Total annual
disclosures
Average
burden per
disclosure
Total hours
Recall Communications (21 CFR 7.49) .....................
tkelley on DSK3SPTVN1PROD with NOTICES
21 CFR Part
3,801
445
1,691,445
0.056 (3 minutes)
94,721
FDA regulates many different types of
products including, but not limited to,
medical products, food and feed,
cosmetics, and tobacco products. FDA
notes that not all third-party disclosures
provided by firms to their consignees
are similar in nature and may entail
different methods and mediums of
communication. FDA estimates the
burden for third-party disclosure per
recall event to be an average of 25 hours.
This burden estimate factored out to the
average number of consignees per recall
(445) results in a burden per disclosure
estimate of approximate hours (25 hours
per recall/445 disclosures/recall = 0.056
hours).
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–02788 Filed 2–10–15; 8:45 am]
Food and Drug Administration
[Docket No. FDA–2011–N–0403]
BILLING CODE 4164–01–P
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Substantiation for
Dietary Supplement Claims Made
Under the Federal Food, Drug, and
Cosmetic Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Frm 00047
Fmt 4703
Sfmt 4703
E:\FR\FM\11FEN1.SGM
Notice.
11FEN1
7611
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by March 13,
2015.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to oira_
submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0626. Also
include the FDA docket number found
in brackets in the heading of this
document.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 8455
Colesville Road; COLE–14526, Silver
Spring, MD 20993–0002 PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUMMARY:
Substantiation for Dietary Supplement
Claims Made Under the Federal Food,
Drug, and Cosmetic Act—21 U.S.C.
343(r)(6) (OMB Control Number 0910–
0626)—Extension
Section 403(r)(6) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act)
(21 U.S.C. 343(r)(6)) requires that a
manufacturer of a dietary supplement
making a nutritional deficiency,
structure/function, or general well-being
claim have substantiation that the claim
is truthful and not misleading. Under
section 403(r)(6)(A) of the FD&C Act,
such a statement is one that ‘‘claims a
benefit related to a classical nutrient
deficiency disease and discloses the
prevalence of such disease in the United
States, describes the role of a nutrient or
dietary ingredient intended to affect the
structure or function in humans,
characterizes the documented
mechanism by which a nutrient or
dietary ingredient acts to maintain such
structure or function, or describes
general well-being from consumption
for a nutrient or dietary ingredient.’’
The guidance document, entitled
‘‘Substantiation for Dietary Supplement
Claims Made Under Section 403(r)(6) of
the Federal Food, Drug, and Cosmetic
Act,’’ provides our recommendations to
manufacturers about the amount, type,
and quality of evidence they should
have to substantiate a claim under
section 403(r)(6) of the FD&C Act. The
guidance does not discuss the types of
claims that can be made concerning the
effect of a dietary supplement on the
structure or function of the body, nor
does it discuss criteria to determine
when a statement about a dietary
supplement is a disease claim. The
guidance document is intended to assist
manufacturers in their efforts to comply
with section 403(r)(6) of the FD&C Act.
Persons with access to the Internet may
obtain the guidance at https://
www.fda.gov/FoodGuidances.
Dietary supplement manufacturers
collect the necessary substantiating
information for their product as
required by section 403(r)(6) of the
FD&C Act. The guidance provides
information to manufacturers to assist
them in doing so. The recommendations
contained in the guidance are voluntary.
Dietary supplement manufacturers will
only need to collect information to
substantiate their product’s nutritional
deficiency, structure/function, or
general well-being claim if they choose
to place a claim on their product’s label.
The standard discussed in the
guidance for substantiation of a claim
on the labeling of a dietary supplement
is consistent with standards set by the
Federal Trade Commission for dietary
supplements and other health-related
products that the claim be based on
competent and reliable scientific
evidence. This evidence standard is
broad enough that some dietary
supplement manufacturers may only
need to collect peer-reviewed scientific
journal articles to substantiate their
claims; other dietary supplement
manufacturers whose products have
properties that are less well documented
may have to conduct studies to build a
body of evidence to support their
claims. It is unlikely that a dietary
supplement manufacturer will attempt
to make a claim when the cost of
obtaining the evidence to support the
claim outweighs the benefits of having
the claim on the product’s label. It is
likely that manufacturers will seek
substantiation for their claims in the
scientific literature.
The time it takes to assemble the
necessary scientific information to
support their claims depends on the
product and the claimed benefits. If the
product is one of several on the market
making a particular claim for which
there is adequate publicly available and
widely established evidence supporting
the claim, then the time to gather
supporting data will be minimal; if the
product is the first of its kind to make
a particular claim or the evidence
supporting the claim is less publicly
available or not widely established, then
gathering the appropriate scientific
evidence to substantiate the claim will
be more time consuming.
In the Federal Register of November
4, 2014 (79 FR 65409), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. Five comments were
received. One comment agreed with the
Agency’s burden estimate while the
remaining comments were not
responsive to four information
collection topics solicited in the notice
and are therefore not discussed in this
document.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeepers
Claim type
Number of
records per
recordkeeper
Total annual
records
Average
burden per
recordkeeping
Total hours
tkelley on DSK3SPTVN1PROD with NOTICES
Widely known, established ..................................................
Pre-existing, not widely established ....................................
Novel ....................................................................................
667
667
667
1
1
1
667
667
667
44
120
120
29,348
80,040
80,040
Total ..............................................................................
........................
........................
........................
........................
189,428
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
We assume that it will take 44 hours
to assemble information needed to
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
substantiate a claim on a particular
dietary supplement when the claim is
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
widely known and established. We
believe it will take closer to 120 hours
E:\FR\FM\11FEN1.SGM
11FEN1
7612
Federal Register / Vol. 80, No. 28 / Wednesday, February 11, 2015 / Notices
to assemble supporting scientific
information when the claim is novel or
when the claim is pre-existing but the
scientific underpinnings of the claim are
not widely established. These are claims
that may be based on emerging science,
where conducting literature searches
and understanding the literature takes
time. It is also possible that references
for claims made for some dietary
ingredients or dietary supplements may
primarily be found in foreign journals
and in foreign languages or in the older,
classical literature where it is not
available on computerized literature
databases or in the major scientific
reference databases, such as the
National Library of Medicine’s literature
database, all of which increases the time
of obtaining substantiation.
In the Federal Register of January 6,
2000 (65 FR 1000), we published a final
rule on statements made for dietary
supplements concerning the effect of the
product on the structure or function of
the body. In that final rule, we estimated
that there were 29,000 dietary
supplement products marketed in the
United States (65 FR 1000 at 1045).
Assuming that the flow of new products
is 10 percent per year, then 2,900 new
dietary supplement products will come
on the market each year. The structure/
function final rule estimated that about
69 percent of dietary supplements have
a claim on their labels, most probably a
structure/function claim (65 FR 1000 at
1046). Therefore, we assume that
supplement manufacturers will need
time to assemble the evidence to
substantiate each of the 2,001 claims
(2,900 × 69 percent) made each year. If
we assume that the 2,001 claims are
equally likely to be pre-existing widely
established claims, novel claims, or preexisting claims that are not widely
established, then we can expect 667 of
each of these types of claims to be
substantiated per year. Table 1 of this
document shows that the annual burden
hours associated with assembling
evidence for claims is 189,428 (the sum
of 667 × 44 hours, 667 × 120 hours, and
667 × 120 hours).
tkelley on DSK3SPTVN1PROD with NOTICES
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015–02787 Filed 2–10–15; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:07 Feb 10, 2015
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–D–0630]
Safety Considerations To Mitigate the
Risks of Misconnections With SmallBore Connectors Intended for Enteral
Applications; Guidance for Industry
and Food and Drug Administration
Staff; Availability
AGENCY:
Food and Drug Administration,
I. Background
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing the
availability of the guidance entitled
‘‘Safety Considerations to Mitigate the
Risks of Misconnections with SmallBore Connectors Intended for Enteral
Applications.’’ The use of common
connector designs, such as Luer
connectors, has led to unintended
connections between devices that have
different intended uses and has resulted
in serious and sometimes fatal
consequences to patients. This guidance
provides recommendations to
manufacturers regarding the
expectations for design and testing of
small-bore connectors intended for
enteral applications (‘‘enteral devices’’).
FDA is making these recommendations
to reduce the risk of unintended
connections between enteral and nonenteral devices.
DATES: Submit either electronic or
written comments on this guidance at
any time. General comments on Agency
guidance documents are welcome at any
time.
ADDRESSES: An electronic copy of the
guidance document is available for
download from the Internet. See the
SUPPLEMENTARY INFORMATION section for
information on electronic access to the
guidance. Submit written requests for a
single hard copy of the guidance
document entitled ‘‘Safety
Considerations to Mitigate the Risks of
Misconnections with Small-Bore
Connectors Intended for Enteral
Applications’’ to the Office of the Center
Director, Guidance and Policy
Development, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5431, Silver Spring,
MD 20993–0002. Send one selfaddressed adhesive label to assist that
office in processing your request.
Submit electronic comments on the
guidance to https://www.regulations.gov.
Submit written comments to the
Division of Dockets Management (HFA–
SUMMARY:
PO 00000
305), Food and Drug Administration,
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852. Identify comments with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Priya Venkataraman-Rao, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. G222,
Silver Spring, MD 20993–0002, 301–
796–6243.
SUPPLEMENTARY INFORMATION:
Frm 00049
Fmt 4703
Sfmt 4703
Numerous publications regarding
patient injury and death from tubing
and catheter misconnections indicate
that reports of misconnections have
increased in frequency over the past
several years. On July 9, 2010, FDA
issued a letter to healthcare
professionals, hospital purchasing
departments, and manufacturers of
enteral feeding tubes regarding Luer
lock misconnections (Ref. 1). FDA
advised manufacturers to assess the
risks of misconnections for their devices
and provide proposed solutions with
validation for premarket review. At that
time, some manufacturers were using
color-coding and labeling to reduce the
risk of misconnections; others were
creating proprietary connectors
designed to be incompatible with
devices for non-enteral applications
(‘‘non-enteral devices’’). However,
recent reports of adverse events have
demonstrated that reliance on colorcoding and tagging of enteral devices
alone cannot adequately mitigate the
risk of misconnections, especially with
similarly color-coded intravenous PICC
(percutaneously inserted central
catheter) lines with Luer connectors.
This guidance provides updated
recommendations to manufacturers of
small-bore connectors intended for
enteral applications. The guidance
recommends that manufacturers: (1)
Design and test enteral connectors based
upon Association for the Advancement
of Medical Instrumentation (AAMI)/
CN3:2014 (PS), ‘‘Small-bore connectors
for liquids and gases in healthcare
applications—Part 3: Connectors for
enteral applications’’ and AAMI/
CN20:2014 (PS), ‘‘Small-bore connectors
for liquids and gases in healthcare
applications—Part 20: Common test
methods’’; (2) for connectors that do not
meet AAMI/CN3:2014 (PS), design and
test connectors based upon the AAMI/
American National Standards Institute
(ANSI)/International Organization for
Standardization (ISO) 80369–1 standard
‘‘Small-bore connectors for liquids and
gases in healthcare applications—Part 1:
E:\FR\FM\11FEN1.SGM
11FEN1
Agencies
[Federal Register Volume 80, Number 28 (Wednesday, February 11, 2015)]
[Notices]
[Pages 7610-7612]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-02787]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0403]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Substantiation for
Dietary Supplement Claims Made Under the Federal Food, Drug, and
Cosmetic Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 7611]]
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by March
13, 2015.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0626.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 8455 Colesville Road; COLE-14526, Silver
Spring, MD 20993-0002 PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Substantiation for Dietary Supplement Claims Made Under the Federal
Food, Drug, and Cosmetic Act--21 U.S.C. 343(r)(6) (OMB Control Number
0910-0626)--Extension
Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the
FD&C Act) (21 U.S.C. 343(r)(6)) requires that a manufacturer of a
dietary supplement making a nutritional deficiency, structure/function,
or general well-being claim have substantiation that the claim is
truthful and not misleading. Under section 403(r)(6)(A) of the FD&C
Act, such a statement is one that ``claims a benefit related to a
classical nutrient deficiency disease and discloses the prevalence of
such disease in the United States, describes the role of a nutrient or
dietary ingredient intended to affect the structure or function in
humans, characterizes the documented mechanism by which a nutrient or
dietary ingredient acts to maintain such structure or function, or
describes general well-being from consumption for a nutrient or dietary
ingredient.''
The guidance document, entitled ``Substantiation for Dietary
Supplement Claims Made Under Section 403(r)(6) of the Federal Food,
Drug, and Cosmetic Act,'' provides our recommendations to manufacturers
about the amount, type, and quality of evidence they should have to
substantiate a claim under section 403(r)(6) of the FD&C Act. The
guidance does not discuss the types of claims that can be made
concerning the effect of a dietary supplement on the structure or
function of the body, nor does it discuss criteria to determine when a
statement about a dietary supplement is a disease claim. The guidance
document is intended to assist manufacturers in their efforts to comply
with section 403(r)(6) of the FD&C Act. Persons with access to the
Internet may obtain the guidance at https://www.fda.gov/FoodGuidances.
Dietary supplement manufacturers collect the necessary
substantiating information for their product as required by section
403(r)(6) of the FD&C Act. The guidance provides information to
manufacturers to assist them in doing so. The recommendations contained
in the guidance are voluntary. Dietary supplement manufacturers will
only need to collect information to substantiate their product's
nutritional deficiency, structure/function, or general well-being claim
if they choose to place a claim on their product's label.
The standard discussed in the guidance for substantiation of a
claim on the labeling of a dietary supplement is consistent with
standards set by the Federal Trade Commission for dietary supplements
and other health-related products that the claim be based on competent
and reliable scientific evidence. This evidence standard is broad
enough that some dietary supplement manufacturers may only need to
collect peer-reviewed scientific journal articles to substantiate their
claims; other dietary supplement manufacturers whose products have
properties that are less well documented may have to conduct studies to
build a body of evidence to support their claims. It is unlikely that a
dietary supplement manufacturer will attempt to make a claim when the
cost of obtaining the evidence to support the claim outweighs the
benefits of having the claim on the product's label. It is likely that
manufacturers will seek substantiation for their claims in the
scientific literature.
The time it takes to assemble the necessary scientific information
to support their claims depends on the product and the claimed
benefits. If the product is one of several on the market making a
particular claim for which there is adequate publicly available and
widely established evidence supporting the claim, then the time to
gather supporting data will be minimal; if the product is the first of
its kind to make a particular claim or the evidence supporting the
claim is less publicly available or not widely established, then
gathering the appropriate scientific evidence to substantiate the claim
will be more time consuming.
In the Federal Register of November 4, 2014 (79 FR 65409), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. Five comments were received. One comment
agreed with the Agency's burden estimate while the remaining comments
were not responsive to four information collection topics solicited in
the notice and are therefore not discussed in this document.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average
Claim type Number of records per Total annual burden per Total hours
recordkeepers recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
Widely known, established....... 667 1 667 44 29,348
Pre-existing, not widely 667 1 667 120 80,040
established....................
Novel........................... 667 1 667 120 80,040
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 189,428
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
We assume that it will take 44 hours to assemble information needed
to substantiate a claim on a particular dietary supplement when the
claim is widely known and established. We believe it will take closer
to 120 hours
[[Page 7612]]
to assemble supporting scientific information when the claim is novel
or when the claim is pre-existing but the scientific underpinnings of
the claim are not widely established. These are claims that may be
based on emerging science, where conducting literature searches and
understanding the literature takes time. It is also possible that
references for claims made for some dietary ingredients or dietary
supplements may primarily be found in foreign journals and in foreign
languages or in the older, classical literature where it is not
available on computerized literature databases or in the major
scientific reference databases, such as the National Library of
Medicine's literature database, all of which increases the time of
obtaining substantiation.
In the Federal Register of January 6, 2000 (65 FR 1000), we
published a final rule on statements made for dietary supplements
concerning the effect of the product on the structure or function of
the body. In that final rule, we estimated that there were 29,000
dietary supplement products marketed in the United States (65 FR 1000
at 1045). Assuming that the flow of new products is 10 percent per
year, then 2,900 new dietary supplement products will come on the
market each year. The structure/function final rule estimated that
about 69 percent of dietary supplements have a claim on their labels,
most probably a structure/function claim (65 FR 1000 at 1046).
Therefore, we assume that supplement manufacturers will need time to
assemble the evidence to substantiate each of the 2,001 claims (2,900 x
69 percent) made each year. If we assume that the 2,001 claims are
equally likely to be pre-existing widely established claims, novel
claims, or pre-existing claims that are not widely established, then we
can expect 667 of each of these types of claims to be substantiated per
year. Table 1 of this document shows that the annual burden hours
associated with assembling evidence for claims is 189,428 (the sum of
667 x 44 hours, 667 x 120 hours, and 667 x 120 hours).
Dated: February 5, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-02787 Filed 2-10-15; 8:45 am]
BILLING CODE 4164-01-P